The MyoSure® tissue removal procedure is a hysteroscopic treatment that enables you to remove abnormal uterine tissue, including fibroids and polyps, under direct visualization.
But how does it compare to other methods? What benefits can it provide to your practice and your patients? One physician recently offered his real-world experiences with the MyoSure procedure.
Otis Lawrence Stitt III, MD, FACOG
Dr. Stitt is the Medical Director at the University of Maryland Minimally Invasive Gynecologic Surgery as well as the Medical Director at the University of Maryland Capital Region Health Fibroid and Pelvic Pain Center. Dr. Stitt is a paid consultant of Hologic.
Past experiences with blind D&C
Dr. Stitt explains, “Before MyoSure, I used blind curettage. This is the way I was trained in residency along with most of my colleagues. We would go in with a hysteroscope, take a peek at the cavity, remove the hysteroscope, and then perform a diagnostic procedure in an effort to obtain a sample for biopsy. I think it’s a philosophy that we were all trained on as gynecological surgeons; however, it leads us to miss certain pathology when we evaluate patients. For example, performing a directed biopsy allows me to see abnormalities that I couldn’t see or allows me to biopsy areas that I couldn’t biopsy with just a blind curettage.”
Making the move to the MyoSure procedure
Dr. Stitt explains what convinced him to move from blind D&C to visualization with the MyoSure procedure: “With MyoSure, we have the ability to perform a directed biopsy, so when we talk about the accuracy of our diagnoses, there is no better accuracy than to see something abnormal and biopsy that thing that you’re seeing.”
Watch Dr. Stitt explain which patients he believes are best suited for the MyoSure procedure:
What makes the MyoSure procedure different
For Dr. Stitt, the quality and versatility of the MyoSure system are what sets it apart. He explains, “I’ve used a lot of hysteroscopes in the past; I’ve used a lot of other curettage equipment. What I found is that with MyoSure, I can remove a number of different types of pathology, whether it’s a small polyp, a 3-centimeter polyp, [or] a small submucosal fibroid.”
But it goes beyond quality and versatility—Dr. Stitt also credits the MyoSure system with improving his accuracy in diagnosing patients. Watch below:
Dr. Stitt speaks to his experience of visualized sampling vs. blind D&C.
According to Dr. Stitt,
“MyoSure is one of my essential tools in my fibroid center. And it’s changed my practice tremendously.”
Learn more by visiting our product page for the MyoSure tissue removal system.
REFERENCE: 1. Loffer FD. The Time Has Come to Quit Relying on a Blind Endometrial Biopsy or Dilation and Curettage to Rule Out Malignant Endometrial Changes. J Minim Invasive Gynecol. 2019;26(7):1207-1208. doi:10.1016/j.jmig.2019.04.011
Important Safety Information
MyoSure Tissue Removal System
The MyoSure® tissue removal system, consisting of the MyoSure tissue removal devices (LITE, REACH, XL) and MyoSure controller, is intended for hysteroscopic intrauterine procedures by trained gynecologists to resect and remove tissue including submucous myomas, endometrial polyps, and retained products of conception. The MyoSure MANUAL hysteroscopic tissue removal device is intended for intrauterine use by a trained gynecologist to hysteroscopically resect and remove tissue, including focal lesions such as endometrial polyps and retained products of conception. MyoSure products are not appropriate for patients who are or may be pregnant, or are exhibiting pelvic infection, cervical malignancies, or previously diagnosed uterine cancer.
For more details on risks and benefits of the MyoSure system, MyoSure MANUAL tissue removal device, MyoSure hysteroscope and the Aquilex® fluid control system, please consult their respective IFUs.